Quest Diagnostics
Thesis
Quest Diagnostics is expected to face secular pressures due to commoditization of services, unfavorable regulations, and increased buyer bargaining power, leading to persistent pricing and volume pressure. The company has been unable to offset cost inflation through its cost savings program and has relied on acquisitions to mask declining profits. A DCF analysis suggests a target price of $35 per share, indicating significant downside from current levels.
Did it work?
Without specific price performance data or a defined time frame since the pitch, it's unclear whether the thesis regarding Quest Diagnostics has played out. The thesis outlines several potential pressures on the company, but without evidence of price movement or confirmation of these dynamics, the outcome remains uncertain.
Raw excerpt
No raw excerpt stored.